A new generation of weight-loss drugs is getting closer to patients. Here's how they differ from Wegovy and Zepbound.

Novo Nordisk's (DK:NOVO.B) next-gen medication is called CagriSema. It's a once-weekly shot that combines a long-acting amylin analogue and Wegovy. Clinical trials found that patients taking CagriSema ...
Healio

Oral agent combined with Wegovy may preserve lean mass for older adults with obesity

A selective androgen receptor modulator combined with a GLP-1 may induce weight loss for older adults with obesity while ...
STAT

Employers drop coverage for weight loss drugs as pharma’s direct-to-consumer programs grow

Doctors and groups representing employers said they’re increasingly hearing about companies cutting weight loss drugs out of ...

Trump’s new website TrumpRx explained: Drug prices could drop by 600%, other lesser-known deals that could bypass insurance

President Trump launched TrumpRx, a new initiative aiming to slash prescription drug costs by forging direct deals with ...

NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?

Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud ...

WHO releases new guidance for GLP-1 weight loss drugs: What to know

The World Health Organization issued new guidance this week on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro ...

Hims & Hers: The Market's Panic Is Irrational

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...